Fibroblast Growth Factor 23: State of the Field and Future Directions

Overview

Journal Trends Endocrinol Metab

Specialty Endocrinology

Date 2012 Aug 28

PMID 22921867

Citations 59

Authors

Nisan Bhattacharyya

William H Chong

Rachel I Gafni

Michael T Collins

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates and is regulated by blood levels of phosphate and active vitamin D. Post-translational glycosylation by the enzyme GALNT3 and subsequent processing by furin have been demonstrated to be a regulated process that plays a role in regulating FGF23 levels. In physiologic states, FGF23 signaling is mediated by an FGF receptor and the coreceptor, Klotho. Recent work identifying a role for iron/hypoxia pathways in FGF23 physiology and their implications are discussed. Beyond its importance in primary disorders of mineral metabolism, recent work implicates FGF23 in renal disease-associated morbidity, as well as possible roles in cardiovascular disease and skeletal fragility.

Citing Articles

Lipocalin 2-A bone-derived anorexigenic and β-cell promoting signal: From mice to humans.

Yang Y, Liu J, Kousteni S J Diabetes. 2023; 16(3):e13504.

PMID: 38035773 PMC: 10940901. DOI: 10.1111/1753-0407.13504.

Fam20c regulates the calpain proteolysis system through phosphorylating Calpasatatin to maintain cell homeostasis.

Liu X, Jiang L, Zhang W, Zhang J, Luan X, Zhan Y J Transl Med. 2023; 21(1):417.

PMID: 37370126 PMC: 10294482. DOI: 10.1186/s12967-023-04275-4.

Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation.

Courbon G, Thomas J, Martinez-Calle M, Wang X, Spindler J, Von Drasek J Blood. 2023; 142(1):106-118.

PMID: 37053547 PMC: 10356820. DOI: 10.1182/blood.2022018475.

FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple sclerosis.

Zhang Q, Chen Z, Zhang K, Zhu J, Jin T CNS Neurosci Ther. 2023; 29(6):1497-1511.

PMID: 36924298 PMC: 10173727. DOI: 10.1111/cns.14176.

A novel mutation in hyperphosphatemic familial tumoral calcinosis and its deleterious effect on protein O-glycosylation.

Zuo Q, Yang W, Liu B, Yan D, Wang Z, Wang H Front Endocrinol (Lausanne). 2022; 13:1008800.

PMID: 36213261 PMC: 9540505. DOI: 10.3389/fendo.2022.1008800.

References

Feng J, Ward L, Liu S, Lu Y, Xie Y, Yuan B . Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38(11):1310-5. PMC: 1839871. DOI: 10.1038/ng1905. View

Bhattacharyya N, Wiench M, Dumitrescu C, Connolly B, Bugge T, Patel H . Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res. 2012; 27(5):1132-41. PMC: 7448291. DOI: 10.1002/jbmr.1546. View

Berndt T, Thomas L, Craig T, Sommer S, Li X, Bergstralh E . Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A. 2007; 104(26):11085-90. PMC: 1891094. DOI: 10.1073/pnas.0704446104. View

Durham B, Joseph F, Bailey L, Fraser W . The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem. 2007; 44(Pt 5):463-6. DOI: 10.1258/000456307781646102. View

Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N . Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009; 45(4):814-6. DOI: 10.1016/j.bone.2009.06.017. View

Antoniucci D, Yamashita T, Portale A . Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006; 91(8):3144-9. DOI: 10.1210/jc.2006-0021. View

Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D . Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med (Berl). 2004; 83(1):33-8. DOI: 10.1007/s00109-004-0610-8. View

Weber T, Liu S, Indridason O, Quarles L . Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003; 18(7):1227-34. DOI: 10.1359/jbmr.2003.18.7.1227. View

Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson K . Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195(1):125-31. DOI: 10.1677/JOE-07-0267. View

10.

Kolek O, Hines E, Jones M, LeSueur L, Lipko M, Kiela P . 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005; 289(6):G1036-42. DOI: 10.1152/ajpgi.00243.2005. View

11.

Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K . Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2009; 95(2):578-85. PMC: 2840849. DOI: 10.1210/jc.2009-1603. View

12.

Knutson M . Iron-sensing proteins that regulate hepcidin and enteric iron absorption. Annu Rev Nutr. 2010; 30:149-71. DOI: 10.1146/annurev.nutr.012809.104801. View

13.

Farrow E, Yu X, Summers L, Davis S, Fleet J, Allen M . Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011; 108(46):E1146-55. PMC: 3219119. DOI: 10.1073/pnas.1110905108. View

14.

Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M . Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol. 2011; 301(2):F371-7. PMC: 3154596. DOI: 10.1152/ajprenal.00740.2010. View

15.

Cai Q, Hodgson S, Kao P, Lennon V, Klee G, Zinsmiester A . Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994; 330(23):1645-9. DOI: 10.1056/NEJM199406093302304. View

16.

Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M . Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007; 18(10):2683-8. DOI: 10.1681/ASN.2006070783. View

17.

Folpe A, Fanburg-Smith J, Billings S, Bisceglia M, Bertoni F, Cho J . Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004; 28(1):1-30. DOI: 10.1097/00000478-200401000-00001. View

18.

Schouten B, Doogue M, Soule S, Hunt P . Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009; 46(Pt 2):167-9. DOI: 10.1258/acb.2008.008151. View

19.

Quarles L . Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol. 2012; 8(5):276-86. PMC: 4489419. DOI: 10.1038/nrendo.2011.218. View

20.

Collins M, Lindsay J, Jain A, Kelly M, Cutler C, Weinstein L . Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. J Bone Miner Res. 2005; 20(11):1944-50. DOI: 10.1359/JBMR.050718. View